Carolina Torronteguy

Publications (4) View all

• Source

  Available from: Carolina Torronteguy

  Article: HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness

  Ana Paula Souza, Caroline Albuquerque, Carolina Torronteguy, Antonio Frasson, Fabio Maito, Luciana Pereira, Vinícius Duval da Silva, Felipe Zerwes, Deborah Raynes, Vince Guerriero, Cristina Bonorino
  [show abstract] [hide abstract]
  ABSTRACT: HspBP1 is a co-chaperone that binds to and regulates the chaperone Hsp70 (Hsp70 is used to refer to HSPA1A and HSPA1B). Hsp70 is known to be elevated in breast tumor tissue, therefore the purpose of these studies was to quantify the expression of HspBP1 in primary breast tumors and in serum of these patients with a follow-up analysis after 6 to 7years. Levels of HspBP1, Hsp70, and anti-HspBP1 antibodies in sera of breast cancer patients and healthy individuals were measured by enzyme-linked immunosorbent assay. Expression of HspBP1 was quantified from biopsies of tumor and normal breast tissue by Western blot analysis. The data obtained were analyzed for association with tumor aggressiveness markers and with patient outcome. The levels of HspBP1 and Hsp70 were significantly higher in sera of patients compared to sera of healthy individuals. HspBP1 antibodies did not differ significantly between groups. HspBP1 levels were significantly higher in tumor (14.46ng/μg protein, n = 51) compared to normal adjacent tissue (3.17ng/μg protein, n = 41, p < 0.001). Expression of HspBP1 was significantly lower in patients with lymph node metastasis and positive for estrogen receptors. HspBP1 levels were also significantly lower in patients with a higher incidence of metastasis and death following a 6 to 7-year follow-up. The HspBP1/Hsp70 molar ratio was not associated with the prognostic markers analyzed. Our results indicate that low HspBP1 expression could be a candidate tumor aggressiveness marker.
  Cell Stress and Chaperones 04/2012; 14(3):301-310. · 3.01 Impact Factor
• Source

  Available from: Carolina Torronteguy

  Article: The Immune System of Cancer Patients

  Carolina Torronteguy, Ana Paula Souza, Cristina Bonorino
  [show abstract] [hide abstract]
  ABSTRACT: Although a great body of evidence is available on the immunosuppressive strategies employed by tumors in order to grow, cancer patients are not considered immunosuppressed individuals. Chemotherapy used in different cancer treatments frequently leads to leucopenia and affects immune responses. Tumors of the immune system can also cause immune alterations, due to their very nature. However, in the absence of preventive routine exams, patients can bear tumors for rather long periods of time without any specific indication, not being particularly prone to contracting infectious diseases compared to cancer free individuals. In this review, we analyze the existing data on the effects of tumors on the immune system of cancer patients. An interesting pattern emerges, suggesting that immunosuppression exerted by tumors is mainly local, rather than systemic. However, some alterations in DCs of cancer patients have been recently described, indicating the interactions between tumor and immune cells may be more complex than previously imagined. This has important implications of the design of anti-tumor therapies as well as in patient quality of life.
  Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu rrent Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents) 01/2012; Vol 10(Issue 4):pp. 262-274.
• Source

  Available from: Carolina Torronteguy

  Article: Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors.

  Carolina Torronteguy, Antonio Frasson, Felipe Zerwes, Erik Winnikov, Vinicius Duval da Silva, Antoine Ménoret, Cristina Bonorino
  [show abstract] [hide abstract]
  ABSTRACT: Heat shock protein (Hsp)-peptide complexes purified from tumors can prime the immune system against tumor antigens, but how they contribute to the generation of immune responses against naturally occurring tumors is unknown. Murine tumors expressing high amounts of Hsp70 are preferentially rejected by the immune system, suggesting that low Hsp70 expression is advantageous for tumor growth in the host. To determine whether Hsp70 was differentially expressed in human tumors, inducible Hsp70 expression was quantitatively (by Western blot) and qualitatively (by immunohistology) analyzed in 53 biopsies of tumor and normal breast tissue. The mean expression of inducible Hsp70 was significantly higher in tumor compared with normal tissue (U = 899.0; P = 0.0033). However, a significant negative association of the amount of Hsp70 expressed by tumor tissue was found with metastasis (r = -0.309; P = 0.05). After 3 years, follow-up analysis determined that 7 of the 53 patients relapsed, and 5 died. Hsp70 expression in tumor (but not normal) cells was significantly lower in relapse patients and patients with metastatic disease than in patients with no relapse or metastasis. Together, these observations support the hypothesis that Hsp70 plays a role in tumor expansion in vivo, and tumors that downregulate it may be able to evade immunosurveillance and grow.
  Cell Stress and Chaperones 02/2006; 11(1):34-43. · 3.01 Impact Factor
• Article: Importância Clínica da Angiogênese Tumoral no Câncer Colorretal

  Carolina Torronteugy, Vinicius Duval da Silva
  Acta Médica (Porto Alegre)/ Pontifícia Universidade Católica do Rio Grande do Sul. Faculdade de Medicina. Hospital São Lucas da PUCRS, 1977.. ISSN 0103-5037. 01/2004; 25(25):pp.529-536.